Price has now gone down to late January levels, where it rose to (from the $2 doldrums) after industry hype about takeovers left, right and centre.
Biocryst holders continue to cling to the desperate hope that they will make a billion on early licensing of one of their candidates, or even better, that the company will be taken out in a multi-billion dollar offer. When you compare the pipeline of Biocryst with Biota's in terms of quality and depth and add the fact that Biota has two revenue earning products and the fact that Biota has a recently awarded $231m US Govt grant (Biocryst's grant is all but expended), how can the two companies actually be compared?
Bring on the US, as long as we get a serious business/investor savvy management and bring on the new management ASAP - their prep-work is required NOW.
BTA Price at posting:
85.0¢ Sentiment: Buy Disclosure: Held